| 2024 | Identification of Potential Genomic Alterations Using Pan-Cancer Cell-Free DNA Next-Generation Sequencing in Patients With Gastric Cancer
| ANNALS OF LABORATORY MEDICINE |
| 2024 | Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
| BRITISH JOURNAL OF CANCER |
| 2023 | Global loss of cellular m6A RNA methylation following infection with different SARS-CoV-2 variants
| GENOME RESEARCH |
| 2022 | Nanomedicine for glioblastoma: Progress and future prospects | SEMINARS IN CANCER BIOLOGY |
| 2022 | Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer
| CANCER CELL INTERNATIONAL |
| 2021 | Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight
| VIRUSES-BASEL |
| 2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
| GASTRIC CANCER |
| 2021 | Detection of EGFR-SEPT14 fusion in cell-free DNA of a patient with advanced gastric cancer: A case report
| WORLD JOURNAL OF CLINICAL CASES |
| 2020 | Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial
| EUROPEAN JOURNAL OF CANCER |
| 2020 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
| GASTRIC CANCER |
| 2020 | Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
| GASTRIC CANCER |
| 2019 | A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01)
| ONCOLOGIST |
| 2019 | A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer | GASTRIC CANCER |
| 2018 | Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype
| Nature Communications |
| 2018 | Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG) | GASTRIC CANCER |
| 2018 | Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY |
| 2018 | Efficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer: a retrospective study
| JOURNAL OF THORACIC DISEASE |
| 2017 | Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy
| PLOS ONE |
| 2017 | Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project | CLINICAL CANCER RESEARCH |
| 2017 | Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score | JAMA ONCOLOGY |
| 2017 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | LANCET |
| 2017 | Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2017 | Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer | CLINICAL CANCER RESEARCH |
| 2017 | Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data
| JOURNAL OF GASTRIC CANCER |
| 2017 | Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01) | CANCER |
| 2016 | Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY |
| 2016 | Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer
| CLINICAL CANCER RESEARCH |
| 2016 | A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction
| ONCOLOGIST |
| 2016 | Overexpression of Endoplasmic Reticulum Oxidoreductin 1-α (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer
| CANCER RESEARCH AND TREATMENT |
| 2016 | Phase II trial of dacomitinib in patients with HER2-positive gastric cancer | GASTRIC CANCER |
| 2016 | Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2015 | Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2015 | 혈액투석 환자에서 발생한 카포시육종의 Pazopanib 치료 증례
| Korean Journal of Medicine |
| 2015 | Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
| CANCER RESEARCH AND TREATMENT |
| 2015 | Comparison of surgery plus chemotherapy and palliative chemotherapy alone for advanced gastric cancer with krukenberg tumor
| CANCER RESEARCH AND TREATMENT |
| 2014 | Clinical practice guidelines for gastric cancer in Korea: An evidence-based approach
| JOURNAL OF GASTRIC CANCER |
| 2014 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | LANCET |
| 2014 | Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
| JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2014 | Targeted therapy in gastric cancer: Personalizing cancer treatment based on patient genome
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2013 | Molecular diagnosis for personalized target therapy in gastric cancer
| JOURNAL OF GASTRIC CANCER |
| 2013 | Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center | THYROID |
| 2013 | Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2013 | 성인에서 천미부 기형종의 선암으로 전환 1예
| Korean Journal of Medicine |
| 2013 | Design of precise third-line therapy for gastric cancer: target or chemotherpy?
| KOREAN JOURNAL OF INTERNAL MEDICINE |
| 2012 | 복강 내에서 발견된 기관지원성낭종 내의 선암 1예
| Korean Journal of Medicine |
| 2012 | Treatment outcome of patients with anaplastic thyroid cancer: a single center experience
| YONSEI MEDICAL JOURNAL |
| 2012 | Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2012 | Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer
| WORLD JOURNAL OF GASTROENTEROLOGY |
| 2012 | Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer | ONCOLOGY |
| 2012 | Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial | LANCET |
http://orcid.org/0000-0002-0926-1819
(36805119200)
